Antitumor effect of gefitinib (‘Iressa’) on esophageal squamous cell carcinoma cell lines in vitro and in vivo

This publication has 26 references indexed in Scilit:

• The Role of Erlotinib (Tarceva, OSI 774) in the Treatment of Non-Small Cell Lung Cancer
  Clinical Cancer Research, 2004
• Multiple Management Modalities in Esophageal Cancer: Combined Modality Management Approaches
  The Oncologist, 2004
• United States Food and Drug Administration Drug Approval Summary
  Clinical Cancer Research, 2004
• The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 (‘Iressa’ ) is not related to the expression of EGFR or HER-2 or to K-ras gene status
  Lung Cancer, 2003
• Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level
  Journal of Cellular Physiology, 2003
• Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2003
• Critical role of both p27^KIP1and p21^CIP1/WAF1 in the antiproliferative effect of ZD1839 (‘Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells
  Journal of Cellular Physiology, 2003
• The ErbB receptor tyrosine family as signal integrators.
  Endocrine-Related Cancer, 2001
• Oesophageal cancer composed of mixed histological types
  European Journal of Surgical Oncology, 1996
• High incidence of egf receptor hyperproduction in esophageal squamous‐cell carcinomas
  International Journal of Cancer, 1987